Adipokine status in pregnant women with irritable bowel syndrome
DOI:
https://doi.org/10.15574/HW.2025.1(176).3844Keywords:
irritable bowel syndrome, pregnancy, adipokines, chemerin, resistin, apelin, extragenital pathologyAbstract
Irritable bowel syndrome (IBS) refers to the disease whose course may be complicated with the onset of pregnancy due to physiological metabolic and adaptive changes to it. The study of concentrations of adipose tissue hormones - adipokines - may be useful for predicting the course of pregnancy and complications in women with IBS.
Aim - to study the anamnesis and course of pregnancy in IBS women.
Materials and methods. 154 women were examined (124 pregnant women from the study group, divided into 2 subgroups depending on the symptomatic/asymptomatic course of IBS; as well as 30 somatically healthy pregnant women from the control group) for anamnestic peculiarities and serum concentrations of chemerin, apelin and resistin. Statistical analysis and presentation of the results were done using the packages "MedStat" and "Microsoft Office Excel". The difference between groups was considered significant at p≤0.05.
Results. During pregnancy an increase in the concentrations of serum pro-inflammatory adipokines is observed, which is a risk factor for exacerbations of IBS. Symptomatic course of IBS is observed in women with significantly higher concentrations of serum adipokines, risk of gestoses (preeclampsia, vomiting of pregnancy), gestational diabetes mellitus and miscarriage are also increased in these women.
Conclusions. Serum concentrations of apelin, chemerin, and resistin in pregnant women can be used as markers predicting the symptomatic course of IBS and IBS itself also contributes to named adipokines elevation, which leads to higher pregnancy complications risk.
The study was conducted in accordance with the principles of the Declaration of Helsinki. The study protocol was approved by the local ethics committee of the participating institution. Informed consent of the patients was obtained for the study.
The authors declare no conflict of interest.
References
Bilooka Y, Fediv O, Stupnytska H, Bilookyi V, Bilookyi O, Rohovyi Y. (2021). The role of adipocytokines and endothelial dysfunction with irritable bowel syndrome associated with obesity. Journal of Education, Health and Sport. 11(7): 219-227. https://doi.org/10.12775/JEHS.2021.11.07.020
Eberlé D, Marousez L, Hanssens S, Knauf C, Breton C et al. (2019). Elabela and Apelin actions in healthy and pathological pregnancies. Cytokine & Growth Factor Reviews. 46: 45-53. https://doi.org/10.1016/j.cytogfr.2019.03.003; PMid:30910349
Ezzat A, Bedair S, Raafat N, Badawy A, Aboulkhair A. (2022). Effect of Estrogen and Progesterone on Irritable Bowel Syndrome in Ovariectomized Albino Rats: A Histological and Immunohistochemical Study. Egyptian Journal of Histology. https://doi.org/10.21608/ejh.2022.124943.1649
Fernandes MD, Daher S, de Sousa LM, Baratto I, Lobo TF et al. (2020). Blood level of adipokines and nutritional status variables in adolescent pregnancy. Obstetrics & Gynecology Science. 63(6): 683-689. https://doi.org/10.5468/ogs.20102; PMid:32898939 PMCid:PMC7677068
Fischbach W. (2023). The diagnosis of irritable bowel syndrome. MMW - Fortschritte der Medizin. 165(16): 36-38. https://doi.org/10.1007/s15006-023-2804-4; PMid:37710116
Girault-Sotias P-E, Deloux R, De Mota N, Riche S, Daubeuf F, Iturrioz X et al. (2024). The metabolically resistant apelin-17 analog LIT01-196 reduces cardiac dysfunction and remodeling in heart failure after myocardial infarction. Canadian Journal of Cardiology. https://doi.org/10.1016/j.cjca.2024.11.034; PMid:39674544
Hu G, Wang Z, Zhang R, Sun W, Chen X. (2021). The Role of Apelin/Apelin Receptor in Energy Metabolism and Water Homeostasis: A Comprehensive Narrative Review. Frontiers in Physiology. 12. https://doi.org/10.3389/fphys.2021.632886; PMid:33679444 PMCid:PMC7928310
Kabbani N, Blüher M, Stepan H, Stumvoll M, Ebert T et al. (2023). Adipokines in Pregnancy: A Systematic Review of Clinical Data. Biomedicines. 11(5): 1419. https://doi.org/10.3390/biomedicines11051419; PMid:37239090 PMCid:PMC10216846
Kukla M, Menżyk T, Dembiński M, Winiarski M, Garlicki A, Bociąga-Jasik M et al. (2021). Anti-inflammatory adipokines: chemerin, vaspin, omentin concentrations and SARS-CoV-2 outcomes. Scientific Reports. 11(1). https://doi.org/10.1038/s41598-021-00928-w; PMid:34728695 PMCid:PMC8563971
Mallardo M, Ferraro S, Daniele A, Nigro E. (2021). GDM-complicated pregnancies: focus on adipokines. Molecular Biology Reports. 48(12): 8171-8180. https://doi.org/10.1007/s11033-021-06785-0; PMid:34652617 PMCid:PMC8604848
Mantaka A, Kalyvianaki K, Kastritsi O, Kampa M, Koutroubakis IE. (2024). Increased Serum Apelin Levels in Patients with Inflammatory Bowel Disease. Gastroenterology Insights. 15(2): 255-265. https://doi.org/10.3390/gastroent15020019
Moyce Gruber BL, Dolinsky VW. (2023). The Role of Adiponectin during Pregnancy and Gestational Diabetes. Life. 13(2): 301. https://doi.org/10.3390/life13020301; PMid:36836658 PMCid:PMC9958871
Nozu T, Miyagishi S, Ishioh M, Takakusaki K, Okumura T. (2022). Peripheral apelin mediates visceral hypersensitivity and impaired gut barrier in a rat irritable bowel syndrome model. Neuropeptides. 94: 102248. https://doi.org/10.1016/j.npep.2022.102248; PMid:35526468
Takeoka A, Kimura T, Hara S, Hamaguchi T, Fukudo S, Tayama J. (2023). Prevalence of Irritable Bowel Syndrome in Japan, China, and South Korea: An International Cross-sectional Study. Journal of Neurogastroenterology and Motility. 29(2): 229-237. https://doi.org/10.5056/jnm22037; PMid:37019867 PMCid:PMC10083109
Thagaard IN, Krebs L, Holm J-C, Lange T, Larsen T, Christiansen M. (2017). Adiponectin and leptin as first trimester markers for gestational diabetes mellitus: a cohort study. Clinical Chemistry and Laboratory Medicine (CCLM). 55(11). https://doi.org/10.1515/cclm-2017-0427; PMid:28763297
Tripathi D, Kant S, Pandey S, Ehtesham NZ. (2020). Resistin in metabolism, inflammation, and disease. The FEBS Journal. 287(15): 3141-3149. https://doi.org/10.1111/febs.15322; PMid:32255270
Vork L, Weerts ZZRM, Mujagic Z, Kruimel JW, Hesselink MAM, Muris JWM et al. (2017). Rome III vs Rome IV criteria for irritable bowel syndrome: A comparison of clinical characteristics in a large cohort study. Neurogastroenterology & Motility. 30(2): e13189. https://doi.org/10.1111/nmo.13189; PMid:28804974
Xie Y, Huang Y, Ling X, Qin H, Wang M, Luo B. (2020). Chemerin/CMKLR1 Axis Promotes Inflammation and Pyroptosis by Activating NLRP3 Inflammasome in Diabetic Cardiomyopathy Rat. Frontiers in Physiology. 11. https://doi.org/10.3389/fphys.2020.00381; PMid:32390873 PMCid:PMC7191320
Yang X, Yao J, Wei Q, Ye J, Yin X, Quan X et al. (2018). Role of chemerin/CMKLR1 in the maintenance of early pregnancy. Frontiers of Medicine. 12(5): 525-532. https://doi.org/10.1007/s11684-017-0577-9; PMid:29556954
Ye Y, Wu P, Wang Y, Yang X, Ye Y, Yuan J et al. (2022). Adiponectin, leptin, and leptin/adiponectin ratio with risk of gestational diabetes mellitus: A prospective nested case-control study among Chinese women. Diabetes Research and Clinical Practice. 191: 110039. https://doi.org/10.1016/j.diabres.2022.110039; PMid:35985429
Youssef MG, Abd El-Hamid K, Sayed OSM, Allam AS. (2022). Serum Resistin Level as a Novel Marker of Disease Activity in Patients with Ulcerative Colitis. The Egyptian Journal of Hospital Medicine. 89(2): 6653-6658. https://doi.org/10.21608/ejhm.2022.270748
Zhang Q, Xiao Z, Lee C-L, Duan Y-G, Fan X, Yeung WSB et al. (2022). The Regulatory Roles of Chemerin-Chemokine-Like Receptor 1 Axis in Placental Development and Vascular Remodeling During Early Pregnancy. Frontiers in Cell and Developmental Biology. 10. https://doi.org/10.3389/fcell.2022.883636; PMid:35656551 PMCid:PMC9152263
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Ukrainian Journal Health of Woman
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The policy of the Journal UKRAINIAN JOURNAL «HEALTH OF WOMAN» is compatible with the vast majority of funders' of open access and self-archiving policies. The journal provides immediate open access route being convinced that everyone – not only scientists - can benefit from research results, and publishes articles exclusively under open access distribution, with a Creative Commons Attribution-Noncommercial 4.0 international license (СС BY-NC).
Authors transfer the copyright to the Journal UKRAINIAN JOURNAL «HEALTH OF WOMAN» when the manuscript is accepted for publication. Authors declare that this manuscript has not been published nor is under simultaneous consideration for publication elsewhere. After publication, the articles become freely available on-line to the public.
Readers have the right to use, distribute, and reproduce articles in any medium, provided the articles and the journal are properly cited.
The use of published materials for commercial purposes is strongly prohibited.
